229 related articles for article (PubMed ID: 11481219)
1. Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure.
Senzaki H; Smith CJ; Juang GJ; Isoda T; Mayer SP; Ohler A; Paolocci N; Tomaselli GF; Hare JM; Kass DA
FASEB J; 2001 Aug; 15(10):1718-26. PubMed ID: 11481219
[TBL] [Abstract][Full Text] [Related]
2. cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism.
Takimoto E; Champion HC; Belardi D; Moslehi J; Mongillo M; Mergia E; Montrose DC; Isoda T; Aufiero K; Zaccolo M; Dostmann WR; Smith CJ; Kass DA
Circ Res; 2005 Jan; 96(1):100-9. PubMed ID: 15576651
[TBL] [Abstract][Full Text] [Related]
3. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5.
Takimoto E; Belardi D; Tocchetti CG; Vahebi S; Cormaci G; Ketner EA; Moens AL; Champion HC; Kass DA
Circulation; 2007 Apr; 115(16):2159-67. PubMed ID: 17420342
[TBL] [Abstract][Full Text] [Related]
4. Sildenafil inhibits beta-adrenergic-stimulated cardiac contractility in humans.
Borlaug BA; Melenovsky V; Marhin T; Fitzgerald P; Kass DA
Circulation; 2005 Oct; 112(17):2642-9. PubMed ID: 16246964
[TBL] [Abstract][Full Text] [Related]
5. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy.
Takimoto E; Champion HC; Li M; Belardi D; Ren S; Rodriguez ER; Bedja D; Gabrielson KL; Wang Y; Kass DA
Nat Med; 2005 Feb; 11(2):214-22. PubMed ID: 15665834
[TBL] [Abstract][Full Text] [Related]
6. PDE5A suppression of acute beta-adrenergic activation requires modulation of myocyte beta-3 signaling coupled to PKG-mediated troponin I phosphorylation.
Lee DI; Vahebi S; Tocchetti CG; Barouch LA; Solaro RJ; Takimoto E; Kass DA
Basic Res Cardiol; 2010 May; 105(3):337-47. PubMed ID: 20107996
[TBL] [Abstract][Full Text] [Related]
7. Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise.
Traverse JH; Chen YJ; Du R; Bache RJ
Circulation; 2000 Dec; 102(24):2997-3002. PubMed ID: 11113052
[TBL] [Abstract][Full Text] [Related]
8. Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure.
Chen HH; Huntley BK; Schirger JA; Cataliotti A; Burnett JC
J Am Soc Nephrol; 2006 Oct; 17(10):2742-7. PubMed ID: 16928803
[TBL] [Abstract][Full Text] [Related]
9. Effect of PDE5 inhibition on coronary hemodynamics in pacing-induced heart failure.
Chen Y; Traverse JH; Hou M; Li Y; Du R; Bache RJ
Am J Physiol Heart Circ Physiol; 2003 May; 284(5):H1513-20. PubMed ID: 12679324
[TBL] [Abstract][Full Text] [Related]
10. Acute Enhancement of Cardiac Function by Phosphodiesterase Type 1 Inhibition.
Hashimoto T; Kim GE; Tunin RS; Adesiyun T; Hsu S; Nakagawa R; Zhu G; O'Brien JJ; Hendrick JP; Davis RE; Yao W; Beard D; Hoxie HR; Wennogle LP; Lee DI; Kass DA
Circulation; 2018 Oct; 138(18):1974-1987. PubMed ID: 30030415
[TBL] [Abstract][Full Text] [Related]
11. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain.
Giordano D; De Stefano ME; Citro G; Modica A; Giorgi M
Biochim Biophys Acta; 2001 May; 1539(1-2):16-27. PubMed ID: 11389965
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase-2 is up-regulated in human failing hearts and blunts β-adrenergic responses in cardiomyocytes.
Mehel H; Emons J; Vettel C; Wittköpper K; Seppelt D; Dewenter M; Lutz S; Sossalla S; Maier LS; Lechêne P; Leroy J; Lefebvre F; Varin A; Eschenhagen T; Nattel S; Dobrev D; Zimmermann WH; Nikolaev VO; Vandecasteele G; Fischmeister R; El-Armouche A
J Am Coll Cardiol; 2013 Oct; 62(17):1596-606. PubMed ID: 23810893
[TBL] [Abstract][Full Text] [Related]
13. Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle.
Park K; Moreland RB; Goldstein I; Atala A; Traish A
Biochem Biophys Res Commun; 1998 Aug; 249(3):612-7. PubMed ID: 9731184
[TBL] [Abstract][Full Text] [Related]
14. Cyclic GMP phosphodiesterase-5: target of sildenafil.
Corbin JD; Francis SH
J Biol Chem; 1999 May; 274(20):13729-32. PubMed ID: 10318772
[No Abstract] [Full Text] [Related]
15. Effect of sildenafil on coronary active and reactive hyperemia.
Chen Y; Du R; Traverse JH; Bache RJ
Am J Physiol Heart Circ Physiol; 2000 Nov; 279(5):H2319-25. PubMed ID: 11045968
[TBL] [Abstract][Full Text] [Related]
16. Type 5 phosphodiesterase inhibition: the focus shifts to the heart.
Semigran MJ
Circulation; 2005 Oct; 112(17):2589-91. PubMed ID: 16246958
[No Abstract] [Full Text] [Related]
17. Phosphodiesterase 5A inhibition induces Na+/H+ exchanger blockade and protection against myocardial infarction.
Pérez NG; Piaggio MR; Ennis IL; Garciarena CD; Morales C; Escudero EM; Cingolani OH; Chiappe de Cingolani G; Yang XP; Cingolani HE
Hypertension; 2007 May; 49(5):1095-103. PubMed ID: 17339532
[TBL] [Abstract][Full Text] [Related]
18. Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine heart.
Forfia PR; Lee M; Tunin RS; Mahmud M; Champion HC; Kass DA
J Am Coll Cardiol; 2007 Mar; 49(10):1079-88. PubMed ID: 17349888
[TBL] [Abstract][Full Text] [Related]
19. Down regulation of myocardial beta1-adrenoceptor signal transduction system in pacing-induced failure in dogs with aortic stenosis-induced left ventricular hypertrophy.
Tse J; Huang MW; Leone RJ; Weiss HR; He YQ; Scholz PM
Mol Cell Biochem; 2000 Feb; 205(1-2):67-73. PubMed ID: 10821423
[TBL] [Abstract][Full Text] [Related]
20. Effects of phosphodiesterase inhibition on cortical spreading depression and associated changes in extracellular cyclic GMP.
Wang M; Urenjak J; Fedele E; Obrenovitch TP
Biochem Pharmacol; 2004 Apr; 67(8):1619-27. PubMed ID: 15041479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
